argenx SE

argenx SE is a commercial-stage biopharmaceutical company focused on developing and delivering innovative antibody-based therapies for severe autoimmune diseases. Operating as a global and fully-integrated entity, the company leverages a suite of advanced antibody engineering technologies and collaborates with disease biology experts to translate immunology discoveries into a robust pipeline of differentiated medicines. Its portfolio features the first approved FcRn blocker, marketed in over 30 countries, addressing unmet needs in autoimmune disorder treatment. argenx SE continues to expand its clinical programs with candidates targeting multiple complex immunological conditions, including a C2 inhibitor in late-stage development and experimental medicines in early proof-of-concept studies. Established in the Netherlands, argenx SE plays a vital role in advancing immunology innovation and improving outcomes for patients worldwide, underscored by its commitment to collaboration and scientific rigor.